(0.10%) 5 251.50 points
(0.01%) 39 644 points
(0.21%) 18 294 points
(-0.37%) $77.97
(-0.58%) $2.24
(-0.69%) $2 358.60
(-0.85%) $28.27
(-0.26%) $1 004.60
(-0.01%) $0.928
(0.17%) $10.85
(-0.04%) $0.798
(-0.50%) $92.21
2 days till quarter result
(tns 2024-05-15)
Expected move: +/- 10.75%
@ $0.286
Issued: 14 Feb 2024 @ 12:10
Return: -68.50%
Previous signal: Feb 13 - 09:38
Previous signal:
Return: 16.83 %
Live Chart Being Loaded With Signals
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types...
Stats | |
---|---|
Today's Volume | 66 253.00 |
Average Volume | 505 170 |
Market Cap | 3.57M |
EPS | $0 ( 2024-04-03 ) |
Next earnings date | ( $-0.350 ) 2024-05-15 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0400 |
ATR14 | $0.00100 (1.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-11 | Orwin John A | Buy | 1 | Series A Junior Preferred Stock |
2024-04-01 | Serafini Tito | Sell | 20 788 | Class A Common Stock |
2023-09-01 | Orwin John A | Sell | 22 951 | Class A Common Stock |
2023-09-01 | Serafini Tito | Sell | 8 393 | Class A Common Stock |
2023-09-01 | Courtney Phillips | Sell | 7 061 | Class A Common Stock |
INSIDER POWER |
---|
26.04 |
Last 95 transactions |
Buy: 4 455 146 | Sell: 2 042 595 |
Atreca Inc Correlation
10 Most Positive Correlations | |
---|---|
GETVV | 0.975 |
ENG | 0.934 |
KZR | 0.92 |
DRCT | 0.918 |
CTMX | 0.917 |
PSTX | 0.916 |
JAN | 0.914 |
ALLK | 0.911 |
DAWN | 0.909 |
CKPT | 0.908 |
10 Most Negative Correlations | |
---|---|
BNIXU | -0.916 |
STAY | -0.907 |
PT | -0.899 |
NVCN | -0.894 |
OPRA | -0.893 |
DSPG | -0.893 |
SGEN | -0.886 |
CCRC | -0.879 |
XLNX | -0.879 |
LFMD | -0.879 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Atreca Inc Financials
Annual | 2022 |
Revenue: | $770 000 |
Gross Profit: | $-6.31M (-819.61 %) |
EPS: | $-2.35 |
FY | 2022 |
Revenue: | $770 000 |
Gross Profit: | $-6.31M (-819.61 %) |
EPS: | $-2.35 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-2.95 |
FY | 2020 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-2.70 |
Financial Reports:
No articles found.
Atreca Inc
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators